← Oncology Approval Tracker

FDA DECISION ·

Lonsurf + bevacizumab

trifluridine + tipiracil + bevacizumab · Taiho Oncology

FDA approvalNew or expanded indicationColorectal cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For metastatic colorectal cancer after fluoropyrimidine, oxaliplatin and irinotecan regimens and an anti-VEGF biologic. RAS wild-type patients also must have received anti-EGFR therapy.

LAMPGEN ANALYSIS

Why it matters

The action added bevacizumab to a previously approved later-line oral regimen.

What research teams should watch

Verify prior drug classes and synchronize oral dosing, blood counts and infusion visits.

PRIMARY RECORDS

Sources